APO Research
Talk to an analyst

APO RESEARCH · REPORT

Phase I - IV Clinical Development Services

Compare research editions
View pricing & licenses

Selected research

Industry Research

Phase I - IV Clinical Development Services Industry Research Report 2026

29 December 2025140 pages

Choose your research edition.

Industry ResearchPhase I - IV Clinical Development Services Industry Research Report 2026140 pages · $2,950 USDIndustry Growth & TrendsGlobal Phase I - IV Clinical Development Services Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Phase I - IV Clinical Development Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Phase I - IV Clinical Development Services Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal Phase I - IV Clinical Development Services Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Phase I - IV Clinical Development Services market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Phase I - IV Clinical Development Services market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Phase I - IV Clinical Development Services market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Phase I - IV Clinical Development Services market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Phase I - IV Clinical Development Services include EPS Group, WuXi AppTec, Beijing Sun-novo Pharmaceutical Research, Elixir Clinical Research, Thermo Fisher Scientific, Dmedglobal, Worldwide Clinical Trial, Synteract and Syneos Health, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Phase I - IV Clinical Development Services market in terms of revenue (US$ million) and, where applicable, service volume (Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Phase I - IV Clinical Development Services.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Phase I - IV Clinical Development Services Market by Company

EPS Group

WuXi AppTec

Beijing Sun-novo Pharmaceutical Research

Elixir Clinical Research

Thermo Fisher Scientific

Dmedglobal

Worldwide Clinical Trial

Synteract

Syneos Health

Sofpromed

Rho, Inc.

Profil

PPD

Parexel

OCT Clinical

LabCorp

ICON Plc

ICBio CRO

GVI CDS

Dynakin

CROS NT

Clinipace

Clinical Leader

Phase I - IV Clinical Development Services Segment by Type

Phase IIIb-IV

Phase II-III

Early Phase

Phase I - IV Clinical Development Services Segment by Application

Contract Research Organizations

Medical Device Companies

Pharmaceutical Companies

Phase I - IV Clinical Development Services Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Phase I - IV Clinical Development Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Phase I - IV Clinical Development Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Phase I - IV Clinical Development Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Phase I - IV Clinical Development Services companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Phase I - IV Clinical Development Services Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Phase I - IV Clinical Development Services Revenue Market Share by Type (2021-2026) Table 7. Global Phase I - IV Clinical Development Services Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Phase I - IV Clinical Development Services Revenue Market Share by Type (2027-2032) Table 9. Global Phase I - IV Clinical Development Services Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Phase I - IV Clinical Development Services Revenue Market Share by Application (2021-2026) Table 11. Global Phase I - IV Clinical Development Services Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Phase I - IV Clinical Development Services Revenue Market Share by Application (2027-2032) Table 13. Global Phase I - IV Clinical Development Services Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Phase I - IV Clinical Development Services Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Phase I - IV Clinical Development Services Market Share by Region (2021-2026) Table 16. Global Phase I - IV Clinical Development Services Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Phase I - IV Clinical Development Services Market Share by Region (2027-2032) Table 18. Phase I - IV Clinical Development Services Industry Trends Table 19. Phase I - IV Clinical Development Services Industry Drivers Table 20. Phase I - IV Clinical Development Services Industry Opportunities and Challenges Table 21. Phase I - IV Clinical Development Services Market Restraints Table 22. Global Top Phase I - IV Clinical Development Services Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Phase I - IV Clinical Development Services Revenue Market Share by Players (2021-2026) Table 24. Global Phase I - IV Clinical Development Services Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Phase I - IV Clinical Development Services, Headquarters and Area Served Table 26. Global Phase I - IV Clinical Development Services Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Phase I - IV Clinical Development Services by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Phase I - IV Clinical Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Phase I - IV Clinical Development Services Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Phase I - IV Clinical Development Services Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Phase I - IV Clinical Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Phase I - IV Clinical Development Services Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Phase I - IV Clinical Development Services Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Phase I - IV Clinical Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Phase I - IV Clinical Development Services Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Phase I - IV Clinical Development Services Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Phase I - IV Clinical Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Phase I - IV Clinical Development Services Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Phase I - IV Clinical Development Services Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Phase I - IV Clinical Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Phase I - IV Clinical Development Services Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Phase I - IV Clinical Development Services Market Size by Country (2027-2032) & (US$ Million) Table 45. EPS Group Company Information Table 46. EPS Group Business Overview Table 47. EPS Group Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 48. EPS Group Phase I - IV Clinical Development Services Product Portfolio Table 49. EPS Group Recent Developments Table 50. WuXi AppTec Company Information Table 51. WuXi AppTec Business Overview Table 52. WuXi AppTec Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 53. WuXi AppTec Phase I - IV Clinical Development Services Product Portfolio Table 54. WuXi AppTec Recent Developments Table 55. Beijing Sun-novo Pharmaceutical Research Company Information Table 56. Beijing Sun-novo Pharmaceutical Research Business Overview Table 57. Beijing Sun-novo Pharmaceutical Research Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 58. Beijing Sun-novo Pharmaceutical Research Phase I - IV Clinical Development Services Product Portfolio Table 59. Beijing Sun-novo Pharmaceutical Research Recent Developments Table 60. Elixir Clinical Research Company Information Table 61. Elixir Clinical Research Business Overview Table 62. Elixir Clinical Research Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 63. Elixir Clinical Research Phase I - IV Clinical Development Services Product Portfolio Table 64. Elixir Clinical Research Recent Developments Table 65. Thermo Fisher Scientific Company Information Table 66. Thermo Fisher Scientific Business Overview Table 67. Thermo Fisher Scientific Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 68. Thermo Fisher Scientific Phase I - IV Clinical Development Services Product Portfolio Table 69. Thermo Fisher Scientific Recent Developments Table 70. Dmedglobal Company Information Table 71. Dmedglobal Business Overview Table 72. Dmedglobal Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 73. Dmedglobal Phase I - IV Clinical Development Services Product Portfolio Table 74. Dmedglobal Recent Developments Table 75. Worldwide Clinical Trial Company Information Table 76. Worldwide Clinical Trial Business Overview Table 77. Worldwide Clinical Trial Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 78. Worldwide Clinical Trial Phase I - IV Clinical Development Services Product Portfolio Table 79. Worldwide Clinical Trial Recent Developments Table 80. Synteract Company Information Table 81. Synteract Business Overview Table 82. Synteract Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 83. Synteract Phase I - IV Clinical Development Services Product Portfolio Table 84. Synteract Recent Developments Table 85. Syneos Health Company Information Table 86. Syneos Health Business Overview Table 87. Syneos Health Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 88. Syneos Health Phase I - IV Clinical Development Services Product Portfolio Table 89. Syneos Health Recent Developments Table 90. Sofpromed Company Information Table 91. Sofpromed Business Overview Table 92. Sofpromed Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 93. Sofpromed Phase I - IV Clinical Development Services Product Portfolio Table 94. Sofpromed Recent Developments Table 95. Rho, Inc. Company Information Table 96. Rho, Inc. Business Overview Table 97. Rho, Inc. Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 98. Rho, Inc. Phase I - IV Clinical Development Services Product Portfolio Table 99. Rho, Inc. Recent Developments Table 100. Profil Company Information Table 101. Profil Business Overview Table 102. Profil Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 103. Profil Phase I - IV Clinical Development Services Product Portfolio Table 104. Profil Recent Developments Table 105. PPD Company Information Table 106. PPD Business Overview Table 107. PPD Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 108. PPD Phase I - IV Clinical Development Services Product Portfolio Table 109. PPD Recent Developments Table 110. Parexel Company Information Table 111. Parexel Business Overview Table 112. Parexel Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 113. Parexel Phase I - IV Clinical Development Services Product Portfolio Table 114. Parexel Recent Developments Table 115. OCT Clinical Company Information Table 116. OCT Clinical Business Overview Table 117. OCT Clinical Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 118. OCT Clinical Phase I - IV Clinical Development Services Product Portfolio Table 119. OCT Clinical Recent Developments Table 120. LabCorp Company Information Table 121. LabCorp Business Overview Table 122. LabCorp Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 123. LabCorp Phase I - IV Clinical Development Services Product Portfolio Table 124. LabCorp Recent Developments Table 125. ICON Plc Company Information Table 126. ICON Plc Business Overview Table 127. ICON Plc Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 128. ICON Plc Phase I - IV Clinical Development Services Product Portfolio Table 129. ICON Plc Recent Developments Table 130. ICBio CRO Company Information Table 131. ICBio CRO Business Overview Table 132. ICBio CRO Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 133. ICBio CRO Phase I - IV Clinical Development Services Product Portfolio Table 134. ICBio CRO Recent Developments Table 135. GVI CDS Company Information Table 136. GVI CDS Business Overview Table 137. GVI CDS Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 138. GVI CDS Phase I - IV Clinical Development Services Product Portfolio Table 139. GVI CDS Recent Developments Table 140. Dynakin Company Information Table 141. Dynakin Business Overview Table 142. Dynakin Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 143. Dynakin Phase I - IV Clinical Development Services Product Portfolio Table 144. Dynakin Recent Developments Table 145. CROS NT Company Information Table 146. CROS NT Business Overview Table 147. CROS NT Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 148. CROS NT Phase I - IV Clinical Development Services Product Portfolio Table 149. CROS NT Recent Developments Table 150. Clinipace Company Information Table 151. Clinipace Business Overview Table 152. Clinipace Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 153. Clinipace Phase I - IV Clinical Development Services Product Portfolio Table 154. Clinipace Recent Developments Table 155. Clinical Leader Company Information Table 156. Clinical Leader Business Overview Table 157. Clinical Leader Revenue in Phase I - IV Clinical Development Services Business (2021-2026) & (US$ Million) Table 158. Clinical Leader Phase I - IV Clinical Development Services Product Portfolio Table 159. Clinical Leader Recent Developments Table 160. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Phase I - IV Clinical Development Services Product Image Figure 5. Global Phase I - IV Clinical Development Services Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Phase I - IV Clinical Development Services Market Share by Type: 2025 VS 2032 Figure 7. Phase IIIb-IV Product Figure 8. Phase II-III Product Figure 9. Early Phase Product Figure 10. Global Phase I - IV Clinical Development Services Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Phase I - IV Clinical Development Services Market Share by Application: 2025 VS 2032 Figure 12. Contract Research Organizations Product Figure 13. Medical Device Companies Product Figure 14. Pharmaceutical Companies Product Figure 15. Global Phase I - IV Clinical Development Services Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 16. Global Phase I - IV Clinical Development Services Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Phase I - IV Clinical Development Services Market Share by Region: 2025 VS 2032 Figure 18. Global Phase I - IV Clinical Development Services Market Share by Players in 2025 Figure 19. Global Phase I - IV Clinical Development Services Manufacturers Established Date Figure 20. Global Top 5 and 10 Phase I - IV Clinical Development Services Players Market Share by Revenue in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. North America Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Phase I - IV Clinical Development Services Market Share by Country (2021-2032) Figure 24. United States Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Canada Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Mexico Phase I - IV Clinical Development Services Market Share by Country (2021-2032) Figure 27. Europe Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 28. Europe Phase I - IV Clinical Development Services Market Share by Country (2021-2032) Figure 29. Germany Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. France Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. U.K. Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Italy Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Spain Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Russia Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Netherlands Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Nordic Countries Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Phase I - IV Clinical Development Services Market Share by Country (2021-2032) Figure 39. China Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. Japan Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. South Korea Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. India Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. India Phase I - IV Clinical Development Services Market Share by Country (2021-2032) Figure 44. Australia Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. China Taiwan Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. Southeast Asia Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South America Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. South America Phase I - IV Clinical Development Services Market Share by Country (2021-2032) Figure 49. Brazil Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Argentina Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Chile Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Colombia Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Peru Phase I - IV Clinical Development Services Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. EPS Group Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 55. WuXi AppTec Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 56. Beijing Sun-novo Pharmaceutical Research Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 57. Elixir Clinical Research Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 58. Thermo Fisher Scientific Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 59. Dmedglobal Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 60. Worldwide Clinical Trial Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 61. Synteract Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 62. Syneos Health Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 63. Sofpromed Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 64. Rho, Inc. Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 65. Profil Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 66. PPD Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 67. Parexel Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 68. OCT Clinical Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 69. LabCorp Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 70. ICON Plc Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 71. ICBio CRO Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 72. GVI CDS Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 73. Dynakin Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 74. CROS NT Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 75. Clinipace Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026) Figure 76. Clinical Leader Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2021-2026)

Scope & coverage.

Types
  • Phase IIIb-IV
  • Phase II-III
  • Early Phase
Applications
  • Contract Research Organizations
  • Medical Device Companies
  • Pharmaceutical Companies
Companies covered
  • EPS Group
  • WuXi AppTec
  • Beijing Sun-novo Pharmaceutical Research
  • Elixir Clinical Research
  • Thermo Fisher Scientific
  • Dmedglobal
  • Worldwide Clinical Trial
  • Synteract
  • Syneos Health
  • Sofpromed
  • Rho, Inc.
  • Profil
  • PPD
  • Parexel
  • OCT Clinical
  • LabCorp
  • ICON Plc
  • ICBio CRO
  • GVI CDS
  • Dynakin
  • CROS NT
  • Clinipace
  • Clinical Leader

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Phase I - IV Clinical Development Services by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Phase IIIb-IV
  5. 2.2.3 Phase II-III
  6. 2.2.4 Early Phase
  7. 2.3 Phase I - IV Clinical Development Services by Application
  8. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  9. 2.3.2 Contract Research Organizations
  10. 2.3.3 Medical Device Companies
  11. 2.3.4 Pharmaceutical Companies
  12. 2.4 Assumptions and Limitations
3 Phase I - IV Clinical Development Services Breakdown Data by Type
  1. 3.1 Global Phase I - IV Clinical Development Services Historic Market Size by Type (2021-2026)
  2. 3.2 Global Phase I - IV Clinical Development Services Forecasted Market Size by Type (2027-2032)
4 Phase I - IV Clinical Development Services Breakdown Data by Application
  1. 4.1 Global Phase I - IV Clinical Development Services Historic Market Size by Application (2021-2026)
  2. 4.2 Global Phase I - IV Clinical Development Services Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Phase I - IV Clinical Development Services Market Perspective (2021-2032)
  2. 5.2 Global Phase I - IV Clinical Development Services Growth Trends by Region
  3. 5.2.1 Global Phase I - IV Clinical Development Services Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Phase I - IV Clinical Development Services Historic Market Size by Region (2021-2026)
  5. 5.2.3 Phase I - IV Clinical Development Services Forecasted Market Size by Region (2027-2032)
  6. 5.3 Phase I - IV Clinical Development Services Market Dynamics
  7. 5.3.1 Phase I - IV Clinical Development Services Industry Trends
  8. 5.3.2 Phase I - IV Clinical Development Services Market Drivers
  9. 5.3.3 Phase I - IV Clinical Development Services Market Challenges
  10. 5.3.4 Phase I - IV Clinical Development Services Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Phase I - IV Clinical Development Services Players by Revenue
  2. 6.1.1 Global Top Phase I - IV Clinical Development Services Players by Revenue (2021-2026)
  3. 6.1.2 Global Phase I - IV Clinical Development Services Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Phase I - IV Clinical Development Services Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Phase I - IV Clinical Development Services Head Office and Area Served
  6. 6.4 Global Phase I - IV Clinical Development Services Players, Product Type & Application
  7. 6.5 Global Phase I - IV Clinical Development Services Manufacturers Established Date
  8. 6.6 Global Phase I - IV Clinical Development Services Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Phase I - IV Clinical Development Services Market Size (2021-2032)
  2. 7.2 North America Phase I - IV Clinical Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Phase I - IV Clinical Development Services Market Size by Country (2021-2026)
  4. 7.4 North America Phase I - IV Clinical Development Services Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Phase I - IV Clinical Development Services Market Size (2021-2032)
  2. 8.2 Europe Phase I - IV Clinical Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Phase I - IV Clinical Development Services Market Size by Country (2021-2026)
  4. 8.4 Europe Phase I - IV Clinical Development Services Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Phase I - IV Clinical Development Services Market Size (2021-2032)
  2. 9.2 Asia-Pacific Phase I - IV Clinical Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Phase I - IV Clinical Development Services Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Phase I - IV Clinical Development Services Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Phase I - IV Clinical Development Services Market Size (2021-2032)
  2. 10.2 South America Phase I - IV Clinical Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Phase I - IV Clinical Development Services Market Size by Country (2021-2026)
  4. 10.4 South America Phase I - IV Clinical Development Services Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Phase I - IV Clinical Development Services Market Size (2021-2032)
  2. 11.2 Middle East & Africa Phase I - IV Clinical Development Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Phase I - IV Clinical Development Services Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Phase I - IV Clinical Development Services Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 EPS Group
  2. 12.1.1 EPS Group Company Information
  3. 12.1.2 EPS Group Business Overview
  4. 12.1.3 EPS Group Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  5. 12.1.4 EPS Group Phase I - IV Clinical Development Services Product Portfolio
  6. 12.1.5 EPS Group Recent Developments
  7. 12.2 WuXi AppTec
  8. 12.2.1 WuXi AppTec Company Information
  9. 12.2.2 WuXi AppTec Business Overview
  10. 12.2.3 WuXi AppTec Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  11. 12.2.4 WuXi AppTec Phase I - IV Clinical Development Services Product Portfolio
  12. 12.2.5 WuXi AppTec Recent Developments
  13. 12.3 Beijing Sun-novo Pharmaceutical Research
  14. 12.3.1 Beijing Sun-novo Pharmaceutical Research Company Information
  15. 12.3.2 Beijing Sun-novo Pharmaceutical Research Business Overview
  16. 12.3.3 Beijing Sun-novo Pharmaceutical Research Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  17. 12.3.4 Beijing Sun-novo Pharmaceutical Research Phase I - IV Clinical Development Services Product Portfolio
  18. 12.3.5 Beijing Sun-novo Pharmaceutical Research Recent Developments
  19. 12.4 Elixir Clinical Research
  20. 12.4.1 Elixir Clinical Research Company Information
  21. 12.4.2 Elixir Clinical Research Business Overview
  22. 12.4.3 Elixir Clinical Research Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  23. 12.4.4 Elixir Clinical Research Phase I - IV Clinical Development Services Product Portfolio
  24. 12.4.5 Elixir Clinical Research Recent Developments
  25. 12.5 Thermo Fisher Scientific
  26. 12.5.1 Thermo Fisher Scientific Company Information
  27. 12.5.2 Thermo Fisher Scientific Business Overview
  28. 12.5.3 Thermo Fisher Scientific Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  29. 12.5.4 Thermo Fisher Scientific Phase I - IV Clinical Development Services Product Portfolio
  30. 12.5.5 Thermo Fisher Scientific Recent Developments
  31. 12.6 Dmedglobal
  32. 12.6.1 Dmedglobal Company Information
  33. 12.6.2 Dmedglobal Business Overview
  34. 12.6.3 Dmedglobal Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  35. 12.6.4 Dmedglobal Phase I - IV Clinical Development Services Product Portfolio
  36. 12.6.5 Dmedglobal Recent Developments
  37. 12.7 Worldwide Clinical Trial
  38. 12.7.1 Worldwide Clinical Trial Company Information
  39. 12.7.2 Worldwide Clinical Trial Business Overview
  40. 12.7.3 Worldwide Clinical Trial Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  41. 12.7.4 Worldwide Clinical Trial Phase I - IV Clinical Development Services Product Portfolio
  42. 12.7.5 Worldwide Clinical Trial Recent Developments
  43. 12.8 Synteract
  44. 12.8.1 Synteract Company Information
  45. 12.8.2 Synteract Business Overview
  46. 12.8.3 Synteract Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  47. 12.8.4 Synteract Phase I - IV Clinical Development Services Product Portfolio
  48. 12.8.5 Synteract Recent Developments
  49. 12.9 Syneos Health
  50. 12.9.1 Syneos Health Company Information
  51. 12.9.2 Syneos Health Business Overview
  52. 12.9.3 Syneos Health Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  53. 12.9.4 Syneos Health Phase I - IV Clinical Development Services Product Portfolio
  54. 12.9.5 Syneos Health Recent Developments
  55. 12.10 Sofpromed
  56. 12.10.1 Sofpromed Company Information
  57. 12.10.2 Sofpromed Business Overview
  58. 12.10.3 Sofpromed Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  59. 12.10.4 Sofpromed Phase I - IV Clinical Development Services Product Portfolio
  60. 12.10.5 Sofpromed Recent Developments
  61. 12.11 Rho, Inc.
  62. 12.11.1 Rho, Inc. Company Information
  63. 12.11.2 Rho, Inc. Business Overview
  64. 12.11.3 Rho, Inc. Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  65. 12.11.4 Rho, Inc. Phase I - IV Clinical Development Services Product Portfolio
  66. 12.11.5 Rho, Inc. Recent Developments
  67. 12.12 Profil
  68. 12.12.1 Profil Company Information
  69. 12.12.2 Profil Business Overview
  70. 12.12.3 Profil Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  71. 12.12.4 Profil Phase I - IV Clinical Development Services Product Portfolio
  72. 12.12.5 Profil Recent Developments
  73. 12.13 PPD
  74. 12.13.1 PPD Company Information
  75. 12.13.2 PPD Business Overview
  76. 12.13.3 PPD Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  77. 12.13.4 PPD Phase I - IV Clinical Development Services Product Portfolio
  78. 12.13.5 PPD Recent Developments
  79. 12.14 Parexel
  80. 12.14.1 Parexel Company Information
  81. 12.14.2 Parexel Business Overview
  82. 12.14.3 Parexel Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  83. 12.14.4 Parexel Phase I - IV Clinical Development Services Product Portfolio
  84. 12.14.5 Parexel Recent Developments
  85. 12.15 OCT Clinical
  86. 12.15.1 OCT Clinical Company Information
  87. 12.15.2 OCT Clinical Business Overview
  88. 12.15.3 OCT Clinical Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  89. 12.15.4 OCT Clinical Phase I - IV Clinical Development Services Product Portfolio
  90. 12.15.5 OCT Clinical Recent Developments
  91. 12.16 LabCorp
  92. 12.16.1 LabCorp Company Information
  93. 12.16.2 LabCorp Business Overview
  94. 12.16.3 LabCorp Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  95. 12.16.4 LabCorp Phase I - IV Clinical Development Services Product Portfolio
  96. 12.16.5 LabCorp Recent Developments
  97. 12.17 ICON Plc
  98. 12.17.1 ICON Plc Company Information
  99. 12.17.2 ICON Plc Business Overview
  100. 12.17.3 ICON Plc Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  101. 12.17.4 ICON Plc Phase I - IV Clinical Development Services Product Portfolio
  102. 12.17.5 ICON Plc Recent Developments
  103. 12.18 ICBio CRO
  104. 12.18.1 ICBio CRO Company Information
  105. 12.18.2 ICBio CRO Business Overview
  106. 12.18.3 ICBio CRO Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  107. 12.18.4 ICBio CRO Phase I - IV Clinical Development Services Product Portfolio
  108. 12.18.5 ICBio CRO Recent Developments
  109. 12.19 GVI CDS
  110. 12.19.1 GVI CDS Company Information
  111. 12.19.2 GVI CDS Business Overview
  112. 12.19.3 GVI CDS Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  113. 12.19.4 GVI CDS Phase I - IV Clinical Development Services Product Portfolio
  114. 12.19.5 GVI CDS Recent Developments
  115. 12.20 Dynakin
  116. 12.20.1 Dynakin Company Information
  117. 12.20.2 Dynakin Business Overview
  118. 12.20.3 Dynakin Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  119. 12.20.4 Dynakin Phase I - IV Clinical Development Services Product Portfolio
  120. 12.20.5 Dynakin Recent Developments
  121. 12.21 CROS NT
  122. 12.21.1 CROS NT Company Information
  123. 12.21.2 CROS NT Business Overview
  124. 12.21.3 CROS NT Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  125. 12.21.4 CROS NT Phase I - IV Clinical Development Services Product Portfolio
  126. 12.21.5 CROS NT Recent Developments
  127. 12.22 Clinipace
  128. 12.22.1 Clinipace Company Information
  129. 12.22.2 Clinipace Business Overview
  130. 12.22.3 Clinipace Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  131. 12.22.4 Clinipace Phase I - IV Clinical Development Services Product Portfolio
  132. 12.22.5 Clinipace Recent Developments
  133. 12.23 Clinical Leader
  134. 12.23.1 Clinical Leader Company Information
  135. 12.23.2 Clinical Leader Business Overview
  136. 12.23.3 Clinical Leader Revenue in Phase I - IV Clinical Development Services Business (2021-2026)
  137. 12.23.4 Clinical Leader Phase I - IV Clinical Development Services Product Portfolio
  138. 12.23.5 Clinical Leader Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst